Sugi Predict

Sugi Predict / Compounds / SCHEMBL221653

SCHEMBL221653

SCHEMBL221653

N#Cc1ccc(C(=O)NN)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 2/20 0.57
▸ CYP3A4 P08684 2/20 0.57
▸ MAOA P21397 1/20 0.57
▸ MAOB P27338 1/20 0.57
▸ KDM5A P29375 1/20 0.57
▸ BLM P54132 1/20 0.57
▸ GFER P55789 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ HIF1A Q16665 1/20 0.57
▸ CA1 P00915 4/20 0.55
▸ CA2 P00918 4/20 0.55
▸ MAPT P10636 2/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ OGG1 O15527 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ LMNA P02545 1/20 0.55
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ GSK3B P49841 2/20 0.55
▸ MEN1 O00255 2/20 0.54
▸ KMT2A Q03164 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28760542 0.98 MAOA (0.56) MPOCYP3A4MAOAMAOBKDM5A
SCHEMBL2830292 0.89 MLYCD (0.66) MAPTLMNAMEN1KMT2ANPC1
SCHEMBL29649031 0.84 SMN1; SMN2 (0.56) CYP3A4MAOACA1CA2MAPT
SCHEMBL18860281 0.83 MPO (0.61) MPOCYP3A4KDM5ABLMGFER
SCHEMBL13590906 0.83 CA1 (0.59) MAOAMAOBCA1CA2ALDH1A1
SCHEMBL30377776 0.82 MPO (0.42) MPOCYP3A4MAOAMAOBKDM5A
SCHEMBL2832357 0.82 KMT2A (0.59) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL343630 0.82 MPO (0.80) MPOCYP3A4KDM5ABLMGFER
SCHEMBL2678949 0.82 MPO (0.80) MPOCYP3A4KDM5ABLMGFER
SCHEMBL15129690 0.81 CA1 (0.57) MAOAMAOBCA1CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025224262-A1 COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR MONTE ROSA THERAPEUTICS AG (CH) 2025-10-30 — — WO disclosed
EP-4608816-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF Monte Rosa Therapeutics AG (CH) 2025-09-03 — — EP disclosed
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2025-08-21 — — US disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
CN-119039173-A Rupestonic acid hydrazide derivative and preparation method and application thereof 喀什大学 2024-11-29 — — CN disclosed
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors ENANTA PHARM INC (US) 2024-10-31 — — US disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 — — CN disclosed
WO-2024092039-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2024-05-02 — — WO disclosed
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2024-04-09 — — US disclosed
US-5668159-A ANTICOAGULANTS FOR CARDIOVASCULAR DISORDERS THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-09-16 — — US disclosed
EP-0710654-A1 TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF THE GREEN CROSS CORPORATION (JP) 1996-05-08 — — EP disclosed
US-5463071-A Tetrazole derivatives; useful for inhibiting undesirable cell aggregation DR. KARL THOMAE GMBH (DE) 1995-10-31 — — US disclosed
US-5336546-A Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 1994-08-09 — — US disclosed
EP-0548366-A1 ORGANIC ELECTROLUMINESCENT ELEMENT IDEMITSU KOSAN COMPANY LIMITED (JP) 1993-06-30 — — EP disclosed
EP-0525629-A2 5-membered heterocycles, process for their preparation and medicaments containing them Dr. Karl Thomae GmbH (DE) 1993-02-03 — — EP disclosed
US-4892964-A Hydrazide-containing thermoplastic polymers exhibiting nonlinear optical response HOECHST CELANESE CORPORATION (US) 1990-01-09 — — US disclosed
US-4824219-A Hydrazide-containing thermoplastic polymers exhibiting nonlinear optical response HOECHST CELANESE CORPORATION (US) 1989-04-25 — — US disclosed
US-4818802-A Hydrazide-containing thermoplastic polymers exhibiting nonlinear optical response HOECHST CELANESE CORP. (US) 1989-04-04 — — US disclosed
EP-0306893-A2 Hydrazide-containing thermoplastic polymers exhibiting nonlinear optical response HOECHST CELANESE CORPORATION (US) 1989-03-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360155-A1 Benzodiazepine Derivatives as RSV Inhibitors GABRA5, GABRA1, GABBR2 MPO 3195/4885CYP3A4 24/4885MAOA 765/4885
US-11952389-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 MPO 3195/4885CYP3A4 24/4885MAOA 765/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 MPO 3195/4885CYP3A4 24/4885MAOA 765/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 MPO 1624/4885CYP3A4 3234/4885MAOA 4377/4885
US-20250263395-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CDK2, SKP2, CDK1 MPO 4367/4885CYP3A4 4346/4885MAOA 3981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.